Discovery of pteridin-7(8 H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant

Journal of Medicinal Chemistry

Volumn 56, Issue 20, 2013, Pages 7821-7837

  Zhou, Wei ^a   Liu, Xiaofeng ^a   Tu, Zhengchao ^b   Zhang, Lianwen ^b   Ku, Xin ^c   Bai, Fang ^d,e   Zhao, Zhenjiang ^a   Xu, Yufang ^a   Ding, Ke ^b   Li, Honglin ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Faculty of Chemical Environmental and Biological Science and Technology   (China)

^e DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPHENYLAMINO) 8 (4 METHOXYPHENYLAMINO)PTERIDIN 7(8H)ONE; 2 (4 AMINOPHENYLAMINO) 8 (4 METHOXYPHENYLAMINO)PTERIDIN 7(8H)ONE; 4 (DIMETHYLAMINO) N [3 (2 (4 METHOXYPHENYLAMINO) 7 OXOPTERIDIN 8(7H) YL)PHENYL]BUT 2 ENAMIDE; 4 (DIMETHYLAMINO) N [3 (7 OXO 2 (PHENYLAMINO)PTERIDIN 8(7H) YL)PHENYL]BUT 2 ENAMIDE; 4 (DIMETHYLAMINO) N [4 (2 (4 METHOXYPHENYLAMINO) 7 OXOPTERIDIN 8(7H) YL)PHENYL]BUT 2 ENAMIDE; 4 (DIMETHYLAMINO) N [4 (7 OXO 2 (PHENYLAMINO)PTERIDIN 8(7H) YL)PHENYL]BUT 2 ENAMIDE; 4 [2 (4 METHOXYPHENYLAMINO) 7 OXOPTERIDIN 8(7H)-YL]PHENYL ACRYLATE; 8 (3 AMINOPHENYL) 2 (4 METHOXYPHENYLAMINO)PTERIDIN 7(8H)ONE; 8 (4 AMINOPHENYL) 2 (4 METHOXYPHENYLAMINO)PTERIDIN 7(8H)ONE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; N [3 (2 (2 METHOXY 4(4 METHYLPIPERAZIN 1 YL)PHENYLAMINO) 7 OXOPTERIDIN 8(7H)PHENYL]ACRYLAMIDE; N [3 (2 (4 (4 METHYLPIPERAZIN 1 YL)PHENYLAMINO) 7 OXOPTERIDIN 8(7H ) YL)PHENYL]ACRYLAMIDE; N [3 (2 (4 (4 METHYLPIPERAZIN 1 YL)PHENYLAMINO) 7 OXOPTERIDIN 8(7H) YL)PHENYL]ACRYLAMIDE; N [3 (2 (4 METHOXYPHENYLAMINO) 7 OXOPTERIDIN 8(7H)-YL)PHENYL]ACRYLAMIDE; N [3 (2 (4 METHOXYPHENYLAMINO) 7 OXOPTERIDIN 8(7H)-YL)PHENYL]PROPIONAMIDE; N [3 (2 (4 MORPHOLINOPHENYLAMINO) 7 OXOPTERIDIN 8(7H ) YL)PHENYL]ACRYLAMIDE; N [3 (7 OXO 2 (4 (PIPERIDIN 1 YL)PHENYLAMINO)PTERIDIN 8(7H ) YL)PHENYL]ACRYLAMIDE; N [3 (7 OXO 2 (4 (PYRROLIDIN 1 YL)PHENYLAMINO)PTERIDIN 8(7H ) YL)PHENYL]ACRYLAMIDE; N [3 (7 OXO 2 (PHENYLAMINO)PTERIDIN 8(7H ) YL)PHENYL]ACRYLAMIDE; N [3 (8 (4 METHOXYPHENYL) 7 OXO 7,8 DIHYDROPTERIDIN 2 YLAMINO)PHENYL]ACRYLAMIDE; N [4 (2 (4 (4 METHYLPIPERAZIN 1 YL)PHENYLAMINO) 7 OXOPTERIDIN 8(7H ) YL)PHENYL]ACRYLAMIDE; N [4 (2 (4 CHLOROPHENYLAMINO) 7 OXOPTERIDIN 8(7H ) YL)PHENYL]ACRYLAMIDE; N [4 (2 (4 METHOXYPHENYLAMINO) 7 OXOPTERIDIN 8(7H) YL)PHENYL]ACRYLAMIDE; N [4 (2 (4 METHOXYPHENYLAMINO) 7 OXOPTERIDIN 8(7H)-YL)PHENYL]ACRYLAMIDE; N [4 (2 (4 METHOXYPHENYLAMINO) 7 OXOPTERIDIN 8(7H)-YL)PHENYL]PROPIONAMIDE; N [4 (2 (4 MORPHOLINOPHENYLAMINO) 7 OXOPTERIDIN 8(7H ) YL)PHENYL]ACRYLAMIDE; N [4 (7 OXO 2 (PHENYLAMINO)PTERIDIN 8(7H ) YL)PHENYL]ACRYLAMIDE; N [4 (8 (4 METHOXYPHENYL) 7 OXO 7,8 DIHYDROPTERIDIN 2 YLAMINO)PHENYL]ACRYLAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WZ 4002;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, SCID; MODELS, CHEMICAL; MOLECULAR STRUCTURE; MUTATION; PROTEIN KINASE INHIBITORS; PTERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886494418     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401045n     Document Type: Article

References (52)

1. Ciardello, F.; Tortora, G. EGFR Antagonists in Cancer Treatment N. Engl. J. Med. 2008, 358, 1160-1174
2. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The ErbB signaling network: Receptor heterodimerization in development and cancer EMBO J. 2000, 19, 3159-3167
3. Sharma, S. V.; Bell, D. W.; Settleman, J.; Haber, D. A. Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 2007, 7, 169-181
4. Wu, C. H.; Coumar, M. S.; Chu, C. Y.; Lin, W. H.; Chen, Y. R.; Chen, C. T.; Shiao, H. Y.; Rafi, S.; Wang, S. Y.; Hsu, H.; Chen, C. H.; Chang, C. Y.; Chang, T. Y.; Lien, T. W.; Fang, M. Y.; Yeh, K. C.; Chen, C. P.; Yeh, T. K.; Hsieh, S. H.; Hsu, J. T.; Liao, C. C.; Chao, Y. S.; Hsieh, H. P. Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: The role of side chain chirality and Michael acceptor group for maximal potency J. Med. Chem. 2010, 53, 7316-7326
5. Janku, F.; Stewart, D. J.; Kurzrock, R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat. Rev. Clin. Oncol. 2011, 8, 384-384
6. Rosell, R.; Moran, T.; Queralt, C.; Porta, R.; Cardenal, F.; Camps, C.; Majem, M.; Lopez-Vivanco, G.; Isla, D.; Provencio, M.; Insa, A.; Massuti, B.; Gonzalez-Larriba, J. L.; Paz-Ares, L.; Bover, I.; Garcia-Campelo, R.; Moreno, M. A.; Catot, S.; Rolfo, C.; Reguart, N.; Palmero, R.; Sánchez, J. M.; Bastus, R.; Mayo, C.; Bertran-Alamillo, J.; Molina, M. A.; Sanchez, J. J.; Taron, M. Screening for epidermal growth factor receptor mutations in lung cancer N. Engl. J. Med. 2009, 361, 958-967
7. Carey, K. D.; Garton, A. J.; Romero, M. S.; Kahler, J.; Thomson, S.; Ross, S.; Park, F.; Haley, J. D.; Gibson, N.; Sliwkowski, M. X. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, Erlotinib Cancer Res. 2006, 66, 8163-8171
8. Yun, C.-H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived egfr mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 2007, 11, 217-227
9. Oxnard, G. R.; Arcila, M. E.; Chmielecki, J.; Ladanyi, M.; Miller, V. A.; Pao, W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer Clin. Cancer Res. 2011, 17, 5530-5537
10. Pallis, A.; Briasoulis, E.; Linardou, H.; Papadimitriou, C.; Bafaloukos, D.; Kosmidis, P.; Murray, S. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: Clinical and molecular considerations Curr. Med. Chem. 2011, 18, 1613-1628
11. Carmi, C.; Lodola, A.; Rivara, S.; Vacondio, F.; Cavazzoni, A.; Alfieri, R. R.; Ardizzoni, A.; Petronini, P. G.; Mor, M. Epidermal growth factor receptor irreversible inhibitors: Chemical exploration of the cysteine-trap portion Mini-Rev. Med. Chem. 2011, 11, 1019-1030
12. Ercan, D.; Zejnullahu, K.; Yonesaka, K.; Xiao, Y.; Capelletti, M.; Rogers, A.; Lifshits, E.; Brown, A.; Lee, C.; Christensen, J. G.; Kwiatkowski, D. J.; Engelman, J. A.; Janne, P. A. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor Oncogene 2010, 29, 2346-2356
13. Gazdar, A. F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 2009, 28, S24-S31
14. Yun, C. H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.; Greulich, H.; Wong, K. K.; Meyerson, M.; Eck, M. J. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2070-2075
15. Zhou, W.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Janne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009, 462, 1070-1074
16. Smaill, J. B.; Showalter, H. D. H.; Zhou, H.; Bridges, A. J.; McNamara, D. J.; Fry, D. W.; Nelson, J. M.; Sherwood, V.; Vincent, P. W.; Roberts, B. J.; Elliott, W. L.; Denny, W. A. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor J. Med. Chem. 2001, 44, 429-440
17. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7665-7670
18. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K, K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 2008, 27, 4702-4711
19. Tsou, H.-R.; Overbeek-Klumpers, E. G.; Hallett, W. A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Michalak, R. S.; Nilakantan, R.; Discafani, C.; Golas, J.; Rabindran, S. K.; Shen, R.; Shi, X.; Wang, Y.-F.; Upeslacis, J.; Wissner, A. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3- carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J. Med. Chem. 2005, 48, 1107-1131
20. Engelman, J. A.; Zejnullahu, K.; Gale, C.-M.; Lifshits, E.; Gonzales, A. J.; Shimamura, T.; Zhao, F.; Vincent, P. W.; Naumov, G. N.; Bradner, J. E.; Althaus, I. W.; Gandhi, L.; Shapiro, G. I.; Nelson, J. M.; Heymach, J. V.; Meyerson, M.; Wong, K.-K.; Jänne, P. A. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to Gefitinib Cancer Res. 2007, 67, 11924-11932
21. Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Greis, K. D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D. J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12022-12027
22. Blair, J. A.; Rauh, D.; Kung, C.; Yun, C.-H.; Fan, Q.-W.; Rode, H.; Zhang, C.; Eck, M. J.; Weiss, W. A.; Shokat, K. M. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics Nat. Chem. Biol. 2007, 3, 229-238
23. Leproult, E.; Barluenga, S.; Moras, D.; Wurtz, J.-M.; Winssinger, N. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: Application to the design of selective covalent inhibitors J. Med. Chem. 2011, 54, 1347-1355
24. Singh, J.; Petter, R. C.; Kluge, A. F. Targeted covalent drugs of the kinase family Curr. Opin. Chem. Biol. 2010, 14, 475-480
25. Karikios, D. J.; Boyer, M. J. Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: Rationale and clinical evidence J. Clin. Invest. 2012, 2, 317-325
26. Ou, S.-H. I. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence Crit. Rev. Oncol. Hematol. 2012, 83, 407-421
27. Bai, F.; Liu, H.; Tong, L.; Zhou, W.; Liu, L.; Zhao, Z.; Liu, X.; Jiang, H.; Wang, X.; Xie, H.; Li, H. Discovery of novel selective inhibitors for EGFR-T790M/L858R Bioorg. Med. Chem. Lett. 2012, 22, 1365-1370
28. Gray, N. S.; Janne, P.; Eck, M. J. EGFR Inhibitors and Methods of Treating Disorders. Patent WO2010129053A2, Nov 11, 2010.
29. Bergmann, R.; Linusson, A.; Zamora, I. SHOP: Scaffold HOPping by GRID-based similarity searches J. Med. Chem. 2007, 50, 2708-2717
30. Lloyd, D. G.; Buenemann, C. L.; Todorov, N. P.; Manallack, D. T.; Dean, P. M. Scaffold hopping in de novo design. Ligand generation in the absence of receptor information J. Med. Chem. 2004, 47, 493-496
31. Jenkins, J. L.; Glick, M.; Davies, J. W. A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes J. Med. Chem. 2004, 47, 6144-6159
32. Barker, E. J.; Buttar, D.; Cosgrove, D. A.; Gardiner, E. J.; Kitts, P.; Willett, P.; Gillet, V. J. Scaffold hopping using clique detection applied to reduced graphs J. Chem. Inf. Model. 2006, 46, 503-511
33. Wale, N.; Watson, I. A.; Karypis, G. Indirect similarity based methods for effective scaffold-hopping in chemical compounds J. Chem. Inf. Model. 2008, 48, 730-741
34. Stiefl, N.; Watson, I. A.; Baumann, K.; Zaliani, A. ErG: 2D pharmacophore descriptions for scaffold hopping J. Chem. Inf. Model. 2006, 46, 208-220
35. Sperandio, O.; Andrieu, O.; Miteva, M. A.; Vo, M.-Q.; Souaille, M.; Delfaud, F.; Villoutreix, B. O. MED-SuMoLig: A new ligand-based screening tool for efficient scaffold hopping J. Chem. Inf. Model. 2007, 47, 1097-1110
36. Rush, T. S.; Grant, J. A.; Mosyak, L.; Nicholls, A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction J. Med. Chem. 2005, 48, 1489-1495
37. Maass, P.; Schulz-Gasch, T.; Stahl, M.; Rarey, M. Recore: A fast and versatile method for scaffold hopping based on small molecule crystal structure conformations J. Chem. Inf. Model. 2007, 47, 390-399
38. Liu, X.; Jiang, H.; Li, H. SHAFTS: A hybrid approach for 3D molecular similarity calculation. 1. Method and Assessment of virtual screening J. Chem. Inf. Model. 2011, 51, 2372-2385
39. Nicholls, A.; McGaughey, G. B.; Sheridan, R. P.; Good, A. C.; Warren, G.; Mathieu, M.; Muchmore, S. W.; Brown, S. P.; Grant, J. A.; Haigh, J. A.; Nevins, N.; Jain, A. N.; Kelley, B. Molecular shape and medicinal chemistry: A perspective J. Med. Chem. 2010, 53, 3862-3886
40. Lu, W.; Liu, X.; Cao, X.; Xue, M.; Liu, K.; Zhao, Z.; Shen, X.; Jiang, H.; Xu, Y.; Huang, J.; Li, H. SHAFTS: A hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration J. Med. Chem. 2011, 54, 3564-3574
41. Voigt, J. H.; Bienfait, B.; Wang, S.; Nicklaus, M. C. Comparison of the NCI open database with seven large chemical structural databases J. Chem. Inf. Comput. Sci. 2001, 41, 702-712
42. Gong, J.; Cai, C.; Liu, X.; Ku, X.; Jiang, H.; Gao, D.; Li, H. ChemMapper: A versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method Bioinformatics 2013, 29, 1827-1829
43. NSC86929 compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/ summary.cgi?cid=258174#x299 (accessed April 2, 2012).
44. Tsou, H.-R.; Mamuya, N.; Johnson, B. D.; Reich, M. F.; Gruber, B. C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc, R.; Davis, R.; Koehn, F. E.; Greenberger, L. M.; Wang, Y.-F.; Wissner, A. 6-Substituted-4-(3- bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity J. Med. Chem. 2001, 44, 2719-2734
45. Chang, S.; Zhang, L.; Xu, S.; Luo, J.; Lu, X.; Zhang, Z.; Xu, T.; Liu, Y.; Tu, Z.; Xu, Y.; Ren, X.; Geng, M.; Ding, J.; Pei, D.; Ding, K. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 → methionine790 mutant J. Med. Chem. 2012, 55, 2711-2723
46. Zhou, W.; Ercan, D.; Jänne, P. A.; Gray, N. S. Discovery of selective irreversible inhibitors for EGFR-T790M Bioorg. Med. Chem. Lett. 2011, 21, 638-643
47. Xu, S.; Zhang, L.; Chang, S.; Luo, J.; Lu, X.; Tu, Z.; Liu, Y.; zhang, Z.; Xu, Y.; Ren, X.; Ding, K. Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790 → methionine790 mutant MedChemComm 2012, 3, 1155-1159
48. Xu, T.; Zhang, L.; Xu, S.; Yang, C.-Y.; Luo, J.; Ding, F.; Lu, X.; Liu, Y.; Tu, Z.; Li, S.; Pei, D.; Cai, Q.; Li, H.; Ren, X.; Wang, S.; Ding, K. Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants Angew. Chem., Int. Ed. 2013, 52, 8387-8390
49. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J.-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336
50. ChemMapper server. http://lilab.ecust.edu.cn/chemmapper/ (accessed April 1, 2012).
51. Liu, X.; Bai, F.; Ouyang, S.; Wang, X.; Li, H.; Jiang, H. Cyndi: A multi-objective evolution algorithm based method for bioactive molecular conformational generation BMC Bioinformatics 2009, 10, 101-1-101-14
52. Liu, K. K. C.; Bagrodia, S.; Bailey, S.; Cheng, H.; Chen, H.; Gao, L.; Greasley, S.; Hoffman, J. E.; Hu, Q.; Johnson, T. O.; Knighton, D.; Liu, Z.; Marx, M. A.; Nambu, M. D.; Ninkovic, S.; Pascual, B.; Rafidi, K.; Rodgers, C. M. L.; Smith, G. L.; Sun, S.; Wang, H.; Yang, A.; Yuan, J.; Zou, A. 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 6096-6099